Research Advances in COPD Drugs and Novel Targets

Abstract

Chronic obstructive pulmonary disease (COPD) is the third-most deadly disease in the world and will be a major healthcare problem for decades to come. Its etiology is mainly related to the exposure to cigarette smoke and poisonous gases, and the infections of viruses including COVID-19 induce acute exacerbation of COPD, which may cause death in patients. Few advances have been made in COPD pathological mechanism, and the current clinical treatment strategies focus on both bronchodilator and anti-inflammatory interventions; but with limited clinical therapeutic agents, COPD therapies still lack more drugs especially those that antagonize COPD-specific inflammatory responses. We review the COPD clinically applied drugs, and the progress of research on new drugs and related novel targets, including [Formula: see text] agonists and anti-muscarinic drugs for airway diastole, glucocorticoids and phosphodiesterase-4 inhibitors for anti-inflammatory, protease inhibitors, emerging antioxidants, adhesion factor inhibitors, growth factor antagonists, adenylate cyclase agonists, chemokine antagonists, etc. We thus provide insights on the COPD new drugs research and development.